【目的】 基于网状Meta分析评价中成药联合吸入疗法对儿童支气管哮喘的疗效及安全性。【方法】 计算机检索中国期刊 全文数据库（CNKI）、中国生物医学文献数据库（CBM）、万方医学数据库（Wanfang Data）、维普信息资源系统（VIP）、 Embase、PubMed、Web of Science 等数据库中收录的中成药联合吸入疗法治疗儿童支气管哮喘的临床随机对照试验，应用 Stata14对数据进行网状Meta分析。【结果】 最终纳入28项研究，包括7种中成药，分别为寒喘祖帕颗粒、槐杞黄颗粒、痰热 清注射液、小儿肺热咳喘颗粒、喘可治注射液、玉屏风颗粒、珠贝定喘丸。网状Meta分析结果显示，在提高总有效率方面， 优选概率排名曲线（surface under the cumulative ranking curve，SUCRA）的概率排序居前3位的依次为痰热清注射液联合吸入疗 法、喘可治注射液联合吸入疗法、珠贝定喘丸联合吸入疗法；改善肺功能指标呼气峰值流速（peak expiratory flow，PEF）、第 1 秒用力呼气容积（forced expiratory volume at one second，FEV1）、FEV1 与用力肺活量（forced vital capacity，FVC）的比值 （FEV1/FVC）最优的干预措施分别为痰热清注射液联合吸入疗法、寒喘祖帕颗粒联合吸入疗法、珠贝定喘丸联合吸入疗法； 对不良反应发生率的SUCRA概率排序的分析结果显示，小儿肺热咳喘颗粒联合吸入疗法可能为副作用最小的干预措施，珠 贝定喘丸联合吸入疗法可能为副作用较大的干预措施。【结论】 中成药联合吸入疗法较单纯吸入疗法可提高小儿支气管哮喘 的有效率及改善肺功能指标，且安全性较好。

Objective To evaluate the efficacy and safety of Chinese patent medicine combined with inhalation therapy for bronchial asthma in children with network meta-analysis. Methods CNKI， CBM， Wanfang Data， VIP，Embase，PubMed，and Web of Science were searched for obtaining the clinical randomized controlled trials of Chinese patent medicine combined with inhalation therapy for the treatment of bronchial asthma in children. Stata14 was used for network meta-analysis of the data. Results A total of 28 studies were eventually included， involving seven kinds of Chinese patent medicines，namely Hanchuan Zupa Granules，Huaiqihuang Granules， Tanreqing Injection， Xiaoer Feire Kechuan Granules， Chuankezhi Injection， Yupingfeng Granules and Zhubei Dingchuan Pills. The results of network meta-analysis showed that for improving the total effective rate，Tanreqing Injection combined with inhalation therapy，Chuankezhi Injection combined with inhalation therapy，and Zhubei Dingchuan Pills combined with inhalation therapy had the top 3 rankings of surface under the cumulative ranking curve（SUCRA）. The optimal intervention measures to improve the peak expiratory flow（PEF），forced expiratory volume at one second（FEV1），and the ratio of FEV1 to forced vital capacity（FEV1/FVC）may separately be Tanreqing Injection combined with inhalation therapy， Hanchuan Zupa Granules combined with inhalation therapy，and Zhubei Dingchuan Pills combined with inhalation therapy. The analysis of the SUCRA ranking of the incidence of adverse reactions showed that Xiaoer Feire Kechuan Granules combined with inhalation therapy may be the intervention with the least side effects，and Zhubei Dingchuan Pills combined with inhalation therapy may be the intervention with greater side effects. Conclusion Compared with inhalation therapy alone， Chinese patent medicine combined with inhalation therapy can enhance the effective rate of bronchial asthma in children and improve lung function indicators，and has good safety.

R256.12

广东省中医药局科研项目（编号：20222242）；东莞市社会发展科技项目（编号：20231800903141）